Wall Street analysts predict that Stemline Therapeutics Inc (NASDAQ:STML) will post earnings of ($0.71) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.85) to ($0.67). Stemline Therapeutics posted earnings of ($0.93) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.7%. The business is scheduled to announce its next quarterly earnings results on Friday, March 15th.
According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($2.80) per share for the current fiscal year, with EPS estimates ranging from ($2.93) to ($2.74). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($2.62) to $1.52. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06).
In other news, COO Kenneth Hoberman sold 26,296 shares of the company’s stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in Stemline Therapeutics by 6.3% in the 3rd quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after purchasing an additional 116,672 shares during the last quarter. Vanguard Group Inc. raised its stake in Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares during the last quarter. Nexthera Capital LP increased its stake in shares of Stemline Therapeutics by 4.0% in the 3rd quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock worth $9,662,000 after acquiring an additional 22,553 shares during the last quarter. Northern Trust Corp increased its stake in shares of Stemline Therapeutics by 12.5% in the 2nd quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock worth $6,106,000 after acquiring an additional 42,262 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in shares of Stemline Therapeutics by 20.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock worth $4,316,000 after acquiring an additional 45,000 shares during the last quarter. 64.20% of the stock is owned by institutional investors and hedge funds.
Stemline Therapeutics stock traded down $0.19 during mid-day trading on Monday, hitting $9.98. The company had a trading volume of 247,177 shares, compared to its average volume of 411,752. Stemline Therapeutics has a 12-month low of $9.65 and a 12-month high of $20.55.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Further Reading: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.